Table 3.
Crude median overall survival and univariable and multivariable Cox proportional hazards regression analyses predicting survival of patients who received palliative chemotherapy for metastatic pancreatic cancer in the period 2005–2013 in the Netherlands
| Characteristics | MS months | Univariable analysis | Multivarivable analysis | ||
|---|---|---|---|---|---|
| HR (95% CI) | P ‐value | HR (95% CI) | P ‐value | ||
| Age | 0.003 | 0.008 | |||
| <70 years | 5.8 | Ref | Ref | ||
| 70–74 years | 6.0 | 0.93 (0.83–1.05) | 0.92 (0.81–1.03) | ||
| 75–79 years | 4.3 | 1.25 (1.05–1.48) | 1.21 (1.02–1.44) | ||
| ≥80 years | 3.7 | 1.58 (1.13–2.21) | 1.48 (1.06–2.07) | ||
| Year of diagnosis | 5.7 | 0.98 (0.96–1.00) | 0.05 | 0.98 (0.96–1.00) | 0.03 |
| Gender | 0.30 | ||||
| Male | 5.5 | Ref | |||
| Female | 6.2 | 0.96 (0.88–1.04) | |||
| History of cancer | 0.85 | ||||
| No | 5.7 | Ref | |||
| Yes | 6.0 | 0.99 (0.86–1.13) | |||
| SES | |||||
| High | 5.8 | Ref | 0.27 | ||
| Medium | 5.5 | 1.05 (0.95–1.16) | |||
| Low | 6.0 | 1.09 (0.98–1.22) | |||
| Tumor verification | 0.02 | 0.007 | |||
| Verification | 5.8 | Ref | Ref | ||
| No verification | 4.9 | 1.19 (1.03–1.37) | 1.22 (1.05–1.41) | ||
| Primary tumor | <0.001 | 0.002 | |||
| Head | 6.2 | Ref | Ref | ||
| Body or tail | 5.4 | 1.21 (1.11–1.33) | 1.17 (1.07–1.29) | ||
| Overlapping/NOS | 5.7 | 1.17 (1.03–1.33) | 1.17 (1.03–1.33) | ||
| Metastatic sites | <0.001 | <0.001 | |||
| 1 | 6.2 | Ref | Ref | ||
| ≥2 | 5.0 | 1.38 (1.25–1.51) | 1.36 (1.23–1.49) | ||
| Unknown | 5.6 | 1.13 (0.82–1.56) | 1.07 (0.76–1.49) | ||
| Sensitivity analysis a | |||||
| Comorbid c. | 0.06 | b | |||
| 0 | 5.8 | Ref | |||
| 1 | 6.0 | 0.97 (0.76–1.23) | |||
| ≥2 | 5.4 | 1.18 (0.96–1.51) | |||
| Unknown | 6.3 | 0.71 (0.49–1.03) | |||
| Comorbid c. | (if yes) | (yes vs. no) | b | ||
| Diabetes | 5.8 | 1.10 (0.87–1.40) | 0.42 | ||
| Cardiac | 5.2 | 0.97 (0.72–1.30) | 0.84 | ||
| Vascular | 4.8 | 1.02 (0.74–1.40) | 0.90 | ||
| Pulmonary | 5.4 | 1.40 (0.96–2.03) | 0.10 | 1.38 (0.94–2.01) | 0.10 |
| Hypertension | 5.8 | 1.16 (0.92–1.46) | 0.22 | ||
| Digestive tract | 7.1 | 0.84 (0.61–1.16) | 0.29 | ||
Survival calculated from date of diagnosis (100% of patients).
MS, median survival; Comorbid c., Comorbid conditions; SES, socioeconomic status; NOS, not otherwise specified; HR, hazard ratio; CI, Confidence Interval.
Region–wide data only n = 420 (18% of all patients). Multivariable model adjusted for variables included in model using nationwide data (age, year of diagnosis, tumor verification, primary tumor, and number of metastatic sites).
Excluding n = 36 patients with unknown comorbid conditions because of collinearity.